BioCryst Receives HSR Act Termination for Astria Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: Dec 03 20250mins
- Antitrust Review Completed: BioCryst Pharmaceuticals announced the early termination of the antitrust review for its acquisition of Astria Therapeutics, satisfying a key condition for the merger, which is expected to close in Q1 2026, thereby accelerating the company's market expansion in rare diseases.
- Strategic Significance of Merger: This merger will enable BioCryst to integrate Astria's R&D resources, advancing its product line in treating hereditary angioedema and other rare diseases, further solidifying its market position and enhancing competitiveness.
- Financial Impact Expectations: BioCryst anticipates incurring significant debt during the merger process, which may affect cash flow management; however, successful integration is expected to yield synergies that enhance overall profitability.
- Investor Attention: BioCryst has filed a registration statement with the SEC regarding the merger, urging investors to carefully read the relevant documents to obtain critical information about the merger and ensure effective participation in shareholder voting post-completion.
BCRX.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on BCRX
Wall Street analysts forecast BCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCRX is 19.27 USD with a low forecast of 8.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 7.660
Low
8.00
Averages
19.27
High
30.00
Current: 7.660
Low
8.00
Averages
19.27
High
30.00
Citizens JMP
Jonathan Wolleben
Outperform
downgrade
$27 -> $25
2025-11-05
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$27 -> $25
2025-11-05
downgrade
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on BioCryst to $25 from $27 and keeps an Outperform rating on the shares following the Q3 earnings report. The firm likes the continued positive trajectory of Orladeyo sales fueled by a growing prescriber base, consistent high patient retention, and strong reimbursement dynamics, the analyst tells investors in a research note. BioCryst is well-positioned for growth, with Orladeyo sales continuing to move higher, pipeline expansion with the strategic addition of navenibart, and potentially de-risking Netherton syndrome data on the horizon, the firm states.
Barclays
Equal Weight
downgrade
$11 -> $9
2025-11-04
Reason
Barclays
Price Target
$11 -> $9
2025-11-04
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on BioCryst to $9 from $11 and keeps an Equal Weight rating on the shares. The company reported an inline Q3 for Orladeyo with narrowed guidance, the analyst tells investors in a research note.
Cantor Fitzgerald
Steve Seedhouse
Overweight
maintain
$24 -> $26
2025-10-15
Reason
Cantor Fitzgerald
Steve Seedhouse
Price Target
$24 -> $26
2025-10-15
maintain
Overweight
Reason
Cantor Fitzgerald analyst Steve Seedhouse raised the firm's price target on BioCryst (BCRX) to $26 from $24 and keeps an Overweight rating on the shares. BioCryst is buying top pick Astria Therapeutics (ATXS) for $700M in enterprise value, and the deal is a "terrific" value for BioCryst, even before accounting for essentially total SG&A synergy, and it allows BioCryst to protect and extend its core HAE commercial leadership position through navenibart's loss of exclusivity in 2042, the analyst tells investors in a research note.
Jefferies
Buy
to
Hold
downgrade
$30 -> $13
2025-10-14
Reason
Jefferies
Price Target
$30 -> $13
2025-10-14
downgrade
Buy
to
Hold
Reason
Jefferies downgraded Astria Therapeutics to Hold from Buy with a price target of $13, down from $30, after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M. The firm expects the deal to close on time in Q1 of 2026.
See All Ratings
About BCRX
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of the HSR Act termination for the merger?
How will integrating Astria's product line benefit BioCryst's portfolio?
How might the merger affect BioCryst's market position in rare diseases by 2026?
Will the anticipated synergies offset the debt incurred during the merger process?